Physician
Psychiatry
Dr. Sheldon H. Preskorn, PHD
|
|
Give Review
Sheldon H. Preskorn, PHD practices Psychiatry. He attended University of Kansas School of Medicine. He received awards:"Regional Top Doctor". Sheldon H. Preskorn, PHD is a published MD as well. He has 100 publications published. The latest was: A Way of Conceptualizing Benzodiazepines to Guide Clinical Use. Sheldon H. Preskorn, PHD is registered with Medicare.
Publications
- A Way of Conceptualizing Benzodiazepines to Guide Clinical Use.
- Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous A...
- CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
- Clinical psychopharmacology and medical malpractice: the four ds.
- The package insert: who writes it and why, what are its implications, and how well does medical school explain it?
- Therapeutic Drug Monitoring (TDM) in Psychiatry (Part I): Why Studies Attempting to Correlate Drug Concentration and Antidepressant Response Don't Work.
- Clinical pharmacology in the development of new antidepressants: the challenges.
- Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with...
- The role of proof of concept (POC) studies in drug development using the EVP-6124 POC study as an example.
- Outliers on the dose-response curve: if the problem is not concentration, then what?
- Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies.
- Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
- A Thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
- Rational Use of Multiple Medications in Medicine and Psychiatry: A Dimensional Perspective.
- Changes in the product label for pimozide illustrate both the promises and the challenges of personalized medicine.
- How Biomarkers Will Change Psychiatry. Part II: Biomarker Selection and Potential Inflammatory Markers of Depression.
- How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction.
- Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.
- The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs.
- What do the terms "drug-specific response/remission rate" and "placebo" really mean?
- Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant?
- How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.
- Phase I trials: from traditional to newer approaches part II.
- Phase I trials: from traditional to newer approaches. Part I.
- CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?
- Inadvertent fatal imipramine poisoning of a child: what happened to Tommy?
- Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-peri...
- The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessmen...
- CNS drug development: part III: future directions.
- CNS drug development: Part II: Advances from the 1960s to the 1990s.
- Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.
- Challenges and opportunities in establishing scientific and regulatory standards for determining therapeutic equivalence of modified-release products: Workshop summary...
- CNS drug development. Part I: The early period of CNS drugs.
- Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary re...
- Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings.
- Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary re...
- Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
- How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
- Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
- Patients who do not respond to the "usual" dose: why Terry fell off the dose-response curve.
- Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation.
- Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report.
- How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part II.
- Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
- How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part I.
- Treatment options for the patient who does not respond well to initial antidepressant therapy.
- What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
- A roadmap to key pharmacologic principles in using antipsychotics: application in clinical practice.
- Neuroscience basis of clinical depression: implications for future antidepressant drug development.
- Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
- Results of the STAR*D study: implications for clinicians and drug developers.
- The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial.
- An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients...
- Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
- Practical application of therapeutic drug monitoring: a tale of two patients.
- Flat dose-response curves for efficacy: what do they mean to the clinician?
- How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
- Deconstructing a medication regimen.
- Multiple medication use presenting as Parkinson''s dementia complex: a message from Titanic.
- Clinical relevance of relative receptor binding affinity: quetiapine and ziprasidone as examples.
- Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don''t see ''em!".
- Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap.
- The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
- Emsam: the first year.
- Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study.
- Mania in a case of polypsychopharmacology: pharmacodynamic and pharmacokinetic considerations. Do you believe in magic?
- Antidepressant drug-drug interactions: clinical relevance and risk management.
- Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.
- Polypharmacy: when is it rational?
- Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.
- The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
- Drugs are an acquired source of biological variance among patients.
- Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
- Detrimental antidepressant drug-drug interactions: are they clinically relevant?
- Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
- Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future.
- Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
- Clinical and demographic factors associated with DSM-IV melancholic depression.
- Patient with bipolar disorder and familial QT prolongation: what to do?
- Single enantiomer drugs: should they be developed?
- Psychopharmacology and psychotherapy: what''s the connection?
- Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance.
- Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.
- Comments on the role of therapeutic drug monitoring for clozapine.
- Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring.
- Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.
- Effect of study criteria on recruitment and generalizability of the results.
- The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
- Drug-drug interactions: proof of relevance (part I).
- D2-blockade and possible ziprasidone-induced galactorrhea.
- Multiple medication use in patients seen in the veterans affairs healthcare system: so what?
- Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients.
- Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers.
- Duloxetine.
- Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses.
- Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
- Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant?
- The recommended dosage range: how is it established and why would it ever be exceeded?
- How drug-drug interactions can impact managed care.
Schools
University of Kansas School of Medicine
University Kans Med Center
Washington University Med Center
Doctors Specialties
- Geriatric Psychiatry
- Psychiatry
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Washington University -
University of Kansas School of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841252566 |
| Last Name Of The Provider | PRESKORN |
| First Name Of The Provider | SHELDON |
| View All |
Similar Doctors
|
|
Dr. Laurie S. Coyner, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Connie M. Marsh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jana Lincoln, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph Bharati, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert F. McIntyre, MD |
|
|
Dr. Vikram Malhotra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan J. Brewer, MD |
|
|
Dr. Tara L. Richardson, MD |
|
|
Dr. Susan L. Carr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Elizabeth A. Burguieres |